Display options
Cite
Villarreal EG, Farias JS, Tweddell JS, et al. Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiol Young. 2021;1-5doi: 10.1017/S1047951121002638.
Villarreal, E. G., Farias, J. S., Tweddell, J. S., Loomba, R. S., & Flores, S. (2021). Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiology in the young, 1-5. https://doi.org/10.1017/S1047951121002638
Villarreal, Enrique G, et al. "Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database." Cardiology in the young vol. (2021): 1-5. doi: https://doi.org/10.1017/S1047951121002638
Villarreal EG, Farias JS, Tweddell JS, Loomba RS, Flores S. Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiol Young. 2021 Jul 08;1-5. doi: 10.1017/S1047951121002638. Epub 2021 Jul 08. PMID: 34233773.
Copy Download .nbib Format: NLM
Share it on

Cardiol Young. 2021 Jul 08;1-5. doi: 10.1017/S1047951121002638. Epub 2021 Jul 08.

Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database.

Cardiology in the young

Enrique G Villarreal, Juan S Farias, James S Tweddell, Rohit S Loomba, Saul Flores

Affiliations

  1. Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico.
  2. Cincinnati Children's Hospital Medical Center, The Heart Center, Cincinnati, OH, USA.
  3. Cardiology, Pediatrics, Advocate Children's Hospital, Oak Lawn, IL, USA.
  4. Medicine, Chicago Medical School/Rosalind Franklin University of Medicine and Science, Chicago, IL, USA.
  5. Texas Children's Hospital, Section of Critical Care and Cardiology/Baylor College of Medicine, Houston, TX, USA.

PMID: 34233773 DOI: 10.1017/S1047951121002638

Abstract

INTRODUCTION: In patients with right ventricular diastolic dysfunction after complete repair of tetralogy of Fallot, some employ the use of beta-blockade. The theoretical benefit of this therapy is felt to be one of the two: 1) reduction in heart rate with subsequent increase in diastolic filling time and stroke volume; 2) halting or reversal of right ventricular remodelling. This study aimed to characterise the use of beta-blockade in paediatric admissions with complete repair of tetralogy of Fallot and characterise the effects of beta-blockade on admission characteristics.

METHODS: Admissions from 2004 to 2015 in the Pediatric Health Information System database with complete repair of tetralogy of Fallot were identified. Characteristics between admissions with and without beta-blockade were compared by univariate analysis. Next, regression analyses were conducted to determine the independent association of beta-blockade on length of admission, billed charges, cardiac arrest, and inpatient mortality while controlling for demographic variables and comorbidities.

RESULTS: A total of 3594 admissions were included in the final analyses. Of these, 371 employed beta-blockade. Admissions with beta-blockade were more likely to have heart failure and tachyarrhythmias. These admissions also tended to be longer by univariate analysis. Regression analyses demonstrated that beta-blockade was independently associated with a 2.8-day increase in length of stay and no statistically significant change in billed charges, cardiac arrest, or inpatient mortality.

CONCLUSIONS: Beta-blockade after complete repair of tetralogy of Fallot is associated with a longer length of stay but did not statistically significantly impact billed charges, cardiac arrest, or inpatient mortality.

Keywords: CHDs; Tetralogy of Fallot; adrenergic beta-antagonists; length of stay; mortality; paediatrics

Publication Types